Guess which ASX healthcare stock just rocketed 46% on major news!

Investors are sending this ASX healthcare stock flying higher on Wednesday. But why?

The All Ordinaries Index (ASX: XAO) is down 0.14% in morning trade, but a little-known ASX healthcare stock is charging in the other direction.

Shares in the healthcare technology company closed yesterday at 5.5 cents and were trading at 8.0 cents apiece after market open today, putting the stock up a blistering 45.5%. After some likely profit-taking, shares are currently changing hands for 6.6 cents, up 20%.

Any guesses?

If you said Alcidion Group Ltd (ASX: ALC), give yourself a virtual gold star.

Here's why investors are sending the ASX healthcare stock flying higher today.

Lab worker puts hands in the air and dances around.

Image source: Getty Images

What's boosting the ASX healthcare stock?

Alcidion is rocketing after the company announced that the North Cumbria Integrated Care NHS Foundation Trust (NCIC) has selected Alcidion as the preferred supplier by for its new Electronic Patient Record (EPR) system.

Located in the United Kingdom, North Cumbria provides hospital and community healthcare for approximately half a million people. The foundation operates across two acute care hospitals, eight community-based hospitals, eight Integrated Care Communities and several support staff locations.

The ASX healthcare stock will provide its Miya Precision platform, including Silverlink PCS, which is already live at NCIC. Alcidion said this will provide clinicians with real-time access to patient records while streamlining patient flow and improving clinical decision-making processes.

Subject to successful negotiation, Alcidion expects this to be a 10-year contract utilising the full Miya Precision product suite along with partner applications.

The total contract value (TCV) remains under negotiation, but Alcidion said it's likely to be between $30 million and $40 million over 10 years.

Alcidion is targeting deployment in the first quarter of calendar year 2025.

What did management say?

Commenting on the contract sending the ASX healthcare stock rocketing today, Alcidion managing director Kate Quirke said, "We are excited to build upon our existing relationship with NCIC by being selected as their preferred EPR supplier."

Quirke continued:

The Alcidion approach of providing an integrated, modular EPR offering allows NCIC to develop their existing digital footprint, protecting their existing investments and allowing them to realise the benefits of additional clinical capabilities such as electronic noting and integrated observations through integration with a number of existing systems.

At a time when the healthcare system is under enormous pressure, we see this increased speed to deliver value as a real opportunity for our customers.

Adrian Clements, executive medical director at NCIC, added:

Over the last few months, many of us have spent a great amount of time evaluating the various Electronic Patient Record systems in order to reach the correct conclusion to help us implement the best possible dynamic EPR system.

I feel assured and confident that selecting Alcidion will allow us to implement an EPR that enables high quality patient care, improves clinical safety and saves clinicians' valuable time.

With today's intraday gains factored in, the ASX healthcare stock is down 10% year to date.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Alcidion Group. The Motley Fool Australia has recommended Alcidion Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Two doctors having a discussion about a patient diagnosis, holding digital tablet.
Healthcare Shares

The hunt for Australia's next CSL: 3 ASX healthcare shares with enormous potential

I look at three healthcare businesses that could be much larger companies in the years ahead.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Should I invest $2,000 into Mesoblast shares?

I look at whether commercial progress has made this long-awaited biotech story worth investing in today.

Read more »

Two colleagues looking at a graph and comparing share prices.
Healthcare Shares

Pro Medicus vs Telix Pharmaceuticals: Which is more likely to double your money in 2 years?

Can Pro Medicus or Telix Pharmaceuticals double your money on the ASX? We stack up their value, growth, and price…

Read more »

Happy doctor using her laptop.
Healthcare Shares

CSL has a new CEO. Are its shares a buy?

I look at what the incoming CEO could bring to the business as its recovery continues.

Read more »

Man holding a calculator with Australian dollar notes, symbolising dividends.
Healthcare Shares

Forget term deposits! I'd buy these ASX dividend shares instead

Term deposits are not exciting to me because of one key reason.

Read more »

A sobbing businessman accused of wrongdoing faces justice
Healthcare Shares

CSL responds to class action, defends disclosure record

The CSL share price is under the microscope after it revealed it will defend a newly filed class action lawsuit.

Read more »

Happy businessman fist pumping while looking at a tablet.
Healthcare Shares

Up 13%: Why is everyone buying Pro Medicus shares this week?

The ASX healthcare shares jumped another 3% on Wednesday.

Read more »

healthcare worker overseeing group of aged care residents at table
Healthcare Shares

Regis Healthcare vs Ryman Healthcare: Which under-the-radar ASX small-cap could double from here?

We compare Regis Healthcare and Ryman Healthcare shares to find out which aged care small-cap could bounce back faster.

Read more »